Vizz FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 4, 2025.
FDA Approved: Yes (First approved July 31, 2025)
Brand name: Vizz
Generic name: aceclidine
Dosage form: Ophthalmic Solution
Previous Name: LNZ100
Company: LENZ Therapeutics, Inc.
Treatment for: Presbyopia
Vizz (aceclidine) is a cholinergic agonist indicated for the treatment of presbyopia in adults.
- Presbyopia is a condition that occurs due to a loss of elasticity in the lens of the eye during the aging process. Symptoms include blurry near vision (trouble seeing things up close and needing to hold reading materials farther away to focus on them), eye strain, and headache.
- Vizz contains aceclidine, an acetylcholine receptor agonist that causes pupil contraction to create a pinhole effect that improves near vision.
- FDA approval of Vizz was based upon results from three randomized, double-masked, controlled Phase 3 CLARITY 1 and CLARITY 2 studies. Both studies achieved all primary and secondary near vision improvement endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. Near vision improvement was reproducible and consistent across both CLARITY 1 and 2.
- Vizz eye drops are administered into each eye once daily (one drop followed by a second drop two minutes later).
- Warnings and precautions associated with Vizz include temporary dim or dark vision after instillation, and rare cases of retinal tears and detachments.
- Common adverse reactions include instillation site irritation (20%), dim vision (16%), and headache (13%).
Development timeline for Vizz
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.